Scutellaria baicalensis is often used to treat breast cancer, but the molecular mechanism
behind the action is unclear. In this study, network pharmacology, molecular docking, and molecular
dynamics simulation are combined to reveal the most active compound in Scutellaria baicalensis and
to explore the interaction between the compound molecule and the target protein in the treatment of
breast cancer. In total, 25 active compounds and 91 targets were screened out, mainly enriched in lipids
in atherosclerosis, the AGE–RAGE signal pathway of diabetes complications, human cytomegalovirus
infection, Kaposi-sarcoma-associated herpesvirus infection, the IL-17 signaling pathway, small-cell
lung cancer, measles, proteoglycans in cancer, human immunodeficiency virus 1 infection, and hepatitis B. Molecular docking shows that the two most active compounds, i.e., stigmasterol and coptisine, could bind well to the target AKT1. According to the MD simulations, the coptisine–AKT1 complex shows higher conformational stability and lower interaction energy than the stigmasterol–AKT1 complex. On the one hand, our study demonstrates that Scutellaria baicalensis has the characteristics of multicomponent and multitarget synergistic effects in the treatment of breast cancer.
On the other hand, we suggest that the best effective compound is coptisine targeting AKT1, which can provide a theoretical basis for the further study of the drug-like active compounds and offer molecular mechanisms behind their roles in the treatment of breast cancer.